Associated tags: Drug development, Medicine, Health, Biotechnology, Pharmaceutical, COVID-19, Research, Cancer, Bio, Science, Patient, Vaccine, Infectious Diseases, Degenerative disease, Neurology, Clinical Trials, Oncology, CTL, Pharmaceutical industry, Clinical trial, Virology
Locations: PHILADELPHIA, NORTH CAROLINA, MASSACHUSETTS, BOSTON, MA, NY, NEW YORK, CAYMAN ISLANDS, DELAWARE, LONG, MONACO, BIO, SEMPER, TIMES SQUARE, WARREN, NJ, US, WALL STREET, UNITED STATES, NORTH AMERICA, NEW JERSEY
Cloud,
Goldman Sachs,
Yale University,
Platform,
Jefferies,
Virology,
Artificial intelligence,
Information technology,
Policy,
Corporate development,
MetLife,
Senior,
Therapy,
Microsoft,
Jefferies Group,
Neurology,
Mobility,
Customer,
CIO,
Bank statement,
Drug discovery,
Biotechnology,
Organization,
Head,
MSIM The Tevogen.ai initiative aims to harness the immense potential of AI to enhance drug discovery, development, manufacturing, distribution, and patient access.
Key Points:
- The Tevogen.ai initiative aims to harness the immense potential of AI to enhance drug discovery, development, manufacturing, distribution, and patient access.
- WARREN, N.J., April 26, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. (“Tevogen” or “Tevogen Bio”) (Nasdaq: TVGN ) is a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in virology, oncology, and neurology.
- Second, I’d like to reflect on our recent leadership appointments and the newly launched initiative in Artificial Intelligence (AI).
- Mr. Shah, a Wall Street veteran with over 25 years of experience across key financial services industry verticals, brings broad leadership capabilities to Tevogen Bio.
TVGN,
Cancer,
Cell,
Woman,
MD,
Virology,
Lymphoma,
Therapy,
Neurology,
Virus,
HPV,
EBV,
Clinical trial,
Viral,
Cervical cancer,
Vaccine Tevogen Bio plans to continue using its ExacTcellTM technology platform to develop additional products targeting cancer causing viruses: HPV for cervical cancer and EBV for lymphoma.
Key Points:
- Tevogen Bio plans to continue using its ExacTcellTM technology platform to develop additional products targeting cancer causing viruses: HPV for cervical cancer and EBV for lymphoma.
- WARREN, N.J., April 11, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings (Tevogen) ( Nasdaq : TVGN ), is a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in virology, oncology, and neurology.
- Neal Flomenberg, MD, Tevogen’s Chief Scientific Officer, explains the company’s oncology pipeline strategy.
- Additional approaches are in development to take this approach even further in the treatment of other cancers.”
WARREN, N.J., April 03, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc (‘Tevogen Bio’) (Nasdaq: TVGN), a clinical-stage biotech company, announces the appointment of Tapan V Shah as Head of Investor Relations and Corporate Development. Mr. Shah, a Wall Street veteran with over 25 years of experience across key financial services industry verticals, brings broad leadership capabilities to Tevogen Bio.
Key Points:
- WARREN, N.J., April 03, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc (‘Tevogen Bio’) (Nasdaq: TVGN ), a clinical-stage biotech company, announces the appointment of Tapan V Shah as Head of Investor Relations and Corporate Development.
- Mr. Shah, a Wall Street veteran with over 25 years of experience across key financial services industry verticals, brings broad leadership capabilities to Tevogen Bio.
- Most recently, Mr. Shah was Director, Relationship Management, in Citigroup’s Client organization, where he was also a member of the Executive Office.
- Prior to Citigroup, he worked in Morgan Stanley’s asset management business (MSIM) focused on Equity Strategy and Product Development.
WARREN, N.J., March 27, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings ('Tevogen Bio') ( Nasdaq : TVGN ), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in virology, oncology, and neurology, has entered into a securities purchase agreement with an existing investor pursuant to which the investor agreed to purchase shares of newly designated Series A-1 Preferred Stock of the Company in lieu of Series A Preferred Stock that the investor earlier agreed to purchase, for an aggregate purchase price of $6.0 million.
Key Points:
- WARREN, N.J., March 27, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings ('Tevogen Bio') ( Nasdaq : TVGN ), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in virology, oncology, and neurology, has entered into a securities purchase agreement with an existing investor pursuant to which the investor agreed to purchase shares of newly designated Series A-1 Preferred Stock of the Company in lieu of Series A Preferred Stock that the investor earlier agreed to purchase, for an aggregate purchase price of $6.0 million.
- The shares of Series A-1 Preferred Stock will be issued in the first quarter and will be convertible at a conversion price of $10.00, as opposed to the $4.00 conversion price of the Series A Preferred Stock, into a total of 600,000 shares of the Company’s common stock at the election of the holder.
- The Series A-1 Preferred Stock is subject to a call right providing the Company the right to call the stock if the volume weighted average price of the common stock for the 20 days prior to delivery of the call notice is greater than $5.00 per share and there is an effective resale registration statement on file covering the underlying common stock.
- The Series A-1 Preferred Stock is non-voting, has no mandatory redemption, carries an annual 5% cumulative dividend, increasing by 2% each year, with a cap of 12% per year.
Retrieved on:
Wednesday, March 20, 2024
COVID-19,
Research,
Clinical Trials,
Biotechnology,
Health,
Pharmaceutical,
General Health,
Other Science,
Science,
TVGN,
COVID,
Mutation,
Immunotherapy,
Patient,
DNP,
SARS-CoV-2,
Genome,
Peptide Tevogen Bio Holdings ('Tevogen Bio') ( Nasdaq : TVGN ), today announced TVGN 489, its investigational allogeneic SARS-CoV-2 specific Cytotoxic CD8+ T lymphocytes (CTLs) immunotherapy for treatment of COVID-19 in high-risk patients and Long COVID, retains activity against the currently dominant and highly mutated JN.1 strain based on a review of this variant’s protein sequences.
Key Points:
- Tevogen Bio Holdings ('Tevogen Bio') ( Nasdaq : TVGN ), today announced TVGN 489, its investigational allogeneic SARS-CoV-2 specific Cytotoxic CD8+ T lymphocytes (CTLs) immunotherapy for treatment of COVID-19 in high-risk patients and Long COVID, retains activity against the currently dominant and highly mutated JN.1 strain based on a review of this variant’s protein sequences.
- TVGN 489 contains Cytotoxic T lymphocytes that recognize multiple SARS-CoV-2 proteins, or peptides.
- TVGN 489’s peptide targets have been preserved in all previously studied COVID strains.
- Continuing surveillance by Tevogen Bio of SARS-CoV-2 variants, including the currently dominant JN.1 strain and newer JN.1 strains, show that 96% of these CTLs remain active against the current circulating variants.
Research,
General Health,
Pharmaceutical,
Oncology,
Technology,
Infectious Diseases,
Artificial Intelligence,
Clinical Trials,
Science,
Biotechnology,
Neurology,
Health,
Risk management,
CSG,
MBA,
American Red Cross,
CSP,
Organization,
Victor,
MPH,
Verita,
Insurance,
Management Tevogen Bio Holdings ('Tevogen Bio') (Nasdaq: TVGN ), congratulates Victor Sordillo PE, CSP, MBA, on his recent appointment as Managing Director of Risk Advisory Services at Verita CSG, Inc., a provider of holistic insurance and risk management solutions for commercial line clients.
Key Points:
- Tevogen Bio Holdings ('Tevogen Bio') (Nasdaq: TVGN ), congratulates Victor Sordillo PE, CSP, MBA, on his recent appointment as Managing Director of Risk Advisory Services at Verita CSG, Inc., a provider of holistic insurance and risk management solutions for commercial line clients.
- Mr. Sordillo has been a vital part of Tevogen’s Board of Directors, contributing to the diversity of thought leadership within the executive team by way of expertise in leadership, risk management, and finance as well as his previous roles on boards of various charitable organizations such as the local chapters of American Red Cross and United Way.
- "Victor's commitment to improving patient access to lifesaving medicines has greatly contributed to the success of Tevogen Bio, and I believe his collaboration with Verita will be just as valuable in bringing innovation to the insurance industry.
- Congratulations!” said Ryan Saadi, MD, MPH, Tevogen Bio’s Chief Executive Officer.
Retrieved on:
Tuesday, February 27, 2024
Software,
Biotechnology,
Networks,
Pharmaceutical,
General Health,
Health,
Artificial Intelligence,
Technology,
Acquisition,
Algorithm,
Multimedia,
Artificial intelligence,
Physician,
Drug development,
Patent,
Public health,
Yale school,
TCR,
Research,
Student,
Medical device Tevogen Bio Holdings – Tevogen (Nasdaq: TVGN ) Chief Information Officer and Head of company’s Artificial Intelligence Initiative, Tevogen.ai , Mittul Mehta, has taken strides to emphasize the importance of proactive talent development for biopharmaceutical sector to allow rapid adoption of artificial intelligence (AI).
Key Points:
- Tevogen Bio Holdings – Tevogen (Nasdaq: TVGN ) Chief Information Officer and Head of company’s Artificial Intelligence Initiative, Tevogen.ai , Mittul Mehta, has taken strides to emphasize the importance of proactive talent development for biopharmaceutical sector to allow rapid adoption of artificial intelligence (AI).
- In his recent seminar at the Yale School of Public Health, “Artificial Intelligence Opportunities in Healthcare,” he underscored the potential of AI in medical innovation and the criticality of talent development.
- This press release features multimedia.
- View the full release here: https://www.businesswire.com/news/home/20240227785694/en/
Mittul Mehta, head of Tevogen's artificial intelligence initiative Tevogen.ai, presenting his seminar “Artificial Intelligence Opportunities in Healthcare” at the Yale School of Public Health (Photo: Business Wire)
“AI represents a unique opportunity to help reduce healthcare costs through many possibilities, including speeding up drug development and aiding in clinical trial design,” said Mr. Mehta.
Retrieved on:
Wednesday, February 21, 2024
Science,
Biotechnology,
Research,
Pharmaceutical,
Health,
COVID-19,
Infectious Diseases,
Clinical Trials,
SARS-CoV-2,
HLA,
MD,
Infection,
Cell,
Risk,
CTL,
Genome,
COVID,
Patient,
Clinical trial,
TVGN,
Vaccine TVGN 489, a CTL therapy produced by the ExactTcell platform, contains CTLs recognizing multiple protein targets across the SARS-CoV-2 genome.
Key Points:
- TVGN 489, a CTL therapy produced by the ExactTcell platform, contains CTLs recognizing multiple protein targets across the SARS-CoV-2 genome.
- Tevogen plans to assess whether TVGN 489 cells can rapidly eliminate symptoms of Long Covid.
- Prior to launching the Long COVID clinical trial, Tevogen seeks to address whether Long COVID occurs more commonly with certain HLA types and less commonly with others, or whether Long COVID occurs randomly in the population regardless of HLA.
- I am highly optimistic that TVGN 489 will offer a meaningful solution for both acute and Long COVID patients,” said Neal Flomenberg, MD, Tevogen’s Chief Scientific Officer.
Retrieved on:
Saturday, February 17, 2024
Tevogen Bio Holdings Inc. ('Tevogen Bio') (Nasdaq: TVGN ) celebrated commencement of its public trading by ringing the opening bell at the Nasdaq Stock Exchange in Times Square, New York, on February 15th, 2024.
Key Points:
- Tevogen Bio Holdings Inc. ('Tevogen Bio') (Nasdaq: TVGN ) celebrated commencement of its public trading by ringing the opening bell at the Nasdaq Stock Exchange in Times Square, New York, on February 15th, 2024.
- This major milestone underscored the company's commitment to its valued shareholders and its mission to develop commercially attractive, affordable, genetically unmodified off-the-shelf T cell therapies for large patient populations in virology, oncology, and neurology.
- “This event not only reconfirmed company’s growth strategy but also reinforced our commitment to our mission.
- As we embark on this new chapter, we look forward to contributing to the market's vibrancy and delivering value to our shareholders and patients.”
Retrieved on:
Thursday, February 15, 2024
On February 14, 2024, Tevogen Bio Holdings Inc. (the “Company”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in virology, oncology, and neurology, entered into a securities purchase agreement with an investor pursuant to which the investor agreed to purchase shares of Series A Preferred Stock of the Company for an aggregate purchase price of $8.0 million.
Key Points:
- On February 14, 2024, Tevogen Bio Holdings Inc. (the “Company”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in virology, oncology, and neurology, entered into a securities purchase agreement with an investor pursuant to which the investor agreed to purchase shares of Series A Preferred Stock of the Company for an aggregate purchase price of $8.0 million.
- “We are excited to begin our journey as a public company with this additional investment,” said Dr. Ryan Saadi, the Company’s Chief Executive Officer and Chairperson.
- “We believe Tevogen’s patient-centric approach, which merges a focus on affordability with advanced science, is a blueprint for sustainable success in the current era of healthcare.
- The Series A Preferred Stock is non-voting, has no mandatory redemption, carries an annual 5% cumulative dividend, increasing by 2% each year.
